CXCL8 and breast carcinoma: The estimated 3- and 6-year breast carcinoma-specific OVS rates for the group of patients carrying or not carrying the IL-8 (-251) A allele were respectively 91.4 and 77.1% versus 75.7 and 45.7% (log rank test, P < 0.002).